References
- 1. Warmke J, Drysdale R, Ganetzky B. A distinct potassium channel polypeptide encoded by the Drosophila eag locus. Science 1991; 252: 1560-2.
- 2. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 1994; 91: 3438-42.
- 3. Martin S, Lino de Oliveira C, Mello de Queiroz F, Pardo LA, Stühmer W, Del Bel E. Eag1 potassium channel immunohistochemistry in the CNS of adult rat and selected regions of human brain. Neuroscience 2008; 155: 833-44.
- 4. Mello de Queiroz F, Suarez-Kurtz G, Stühmer W, Pardo LA. Ether à go-go potassium channel expression in soft tissue sarcoma patients. Mol Cancer 2006; 5: 42.
- 5. Hemmerlein B, Weseloh RM, Mello de Queiroz F, Knötgen H, Sánchez A, Rubio ME, et al. Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer 2006; 5: 41.
- 6. Downie BR, Sánchez A, Knötgen H, Contreras-Jurado C, Gymnopoulos M, Weber C, et al. Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. J Biol Chem 2008; 283: 36234-40.
- 7. Restrepo-Angulo I, Sánchez-Torres C, Camacho J. Human EAG1 potassium channels in the epithelial-to-mesenchymal transition in lung cancer cells. Anticancer Res 2011; 31: 1265-70.
- 8. Weber C, Mello de Queiroz F, Downie BR, Suckow A, Stühmer W, Pardo LA. Silencing the activity and proliferative properties of the human EagI Potassium Channel by RNA Interference. J Biol Chem 2006; 281: 13030-7.
- 9. García-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stühmer W, Pardo LA. Mechanism of block of hEag1 K+ channels by imipramine and astemizole. J Gen Physiol 2004; 124: 301-7.
- 10. Ding XW, Luo HS, Jin X, Yan JJ, Ai YW. Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines. Med Oncol 2007; 24: 345-50.
- 11. Camacho J. Ether à go-go potassium channels and cancer. Cancer Lett 2006; 233: 1-9.
- 12. Pardo LA, Sühmer W. Eag1 as cancer target. Expert Opin Ther Targets 2008; 12: 837-43.
- 13. Agarwal JR, Griesinger F, Stühmer W, Pardo LA. The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer 2010; 9: 18.
- 14. Rastegar F, Gao JL, Shenaq D, Luo Q, Shi Q, Kim SH, et al. Lysophosphatidic acid acyltransferase β (LPAATβ) promotes the tumor growth of human osteosarcoma. PLoS ONE 2010; 5: e14182.
- 15. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006; 32: 423-6.
- 16. Kachanov DY, Dobrenkov KV, ShamanskayaTV, Abdullaev RT, Inushkina EV, Savkova RF et al. Solid tumors in young children in Moscow Region of Russian Federation. Radiol Oncol 2008; 42: 39-44.
- 17. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-90.
- 18. Fagioli F, Aglietta M, Tienghi A, Ferrari S, Brach del Prever A,Vassallo E, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2002; 20: 2150-6.
- 19. Marina N, Gorlick R. Immune approaches to treating osteosarcoma. CancerBiol Ther 2009; 8: 981-3.
- 20. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-14.
- 21. Gao YS, Mei J, Tong TL, Hu M, Xue HM, Cai XS. Inhibitory effects of VEGFsiRNA mediated by adenovirus on osteosarcoma-bearing nude mice. Cancer Biother Radiopharm 2009; 24: 243-7.
- 22. Hegle AP, Marble DD, Wilson GF. A voltage-driven switch for ion-independent signaling by ether-a-go-go K+ channels. Proc Natl Acad Sci USA. 2006; 103: 2886-91.
- 23. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-49.
- 24. Rebersek M, Boc M, Cerkovnik P, Benedik J, Hlebanja Z, Volk N, et al. Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis. Radiol Oncol 2011; 45: 285-91.
- 25. Bulavin DV, Kovalsky O, Hollander MC, Fornace AJ Jr. Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a. Mol Cell Biol 2003; 23: 3859-71.
- 26. Cardaci S, Filomeni G, Rotilio G, Ciriolo MR. p38(MAPK)/p53 signalling axis mediates neuronal apoptosis in response to tetrahydrobiopterin-induced oxidative stress and glucose uptake inhibition: implication for neurodegeneration. Biochem J 2010; 430: 439-51.
- 27. Ouadid-Ahidouch H, Le Bourhis X, Roudbaraki M, Toillon RA, Delcourt P, N Prevarskaya. Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: possible involvement of a h-ether.a-gogo K+ channel. Receptors Channels 2001; 7: 345-56.
- 28. Asher V, Warren A, Shaw R, Sowter H, Bali A, Khan R. The role of Eag and HERG channels in cell proliferation and apoptotic cell death in SK-OV-3 ovarian cancer cell line. Cancer Cell Int 2011; 11: 6.
- 29. Gavrilova-Ruch O, Schönherr K, Gessner G, Schönherr R, Klapperstück T, Wohlrab W, et al. Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J Membr Biol 2002; 188: 137-49.
- 30. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003; 101: 4667-79.
- 31. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, et al.
- Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J BiolChem 2003; 278: 19245-56.
- 32. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005; 6: 322-7.
- 33. Kraunz KS, Nelson HH, Liu M, Wiencke JK, Kelsey KT. Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer. Br J Cancer 2005; 93: 949-52.
- 34. Sasaki K, Hitora T, Nakamura O, Kono R, Yamamoto T. The role of MAPK pathway in bone and soft tissue tumors. Anticancer Res 2011; 31: 549-53.
- 35. Shimo T, Matsumura S, Ibaragi S, Isowa S, Kishimoto K, Mese H, et al. Specific inhibitor of MEK-mediated cross-talk between ERK and p38 MAPK during differentiation of human osteosarcoma cells. J Cell Commun Signal 2007; 1: 103-11.
- 36. Asher V, Sowter H, Shaw R, Bali A, Khan R. Eag and HERG potassium channels as novel therapeutic targets in cancer. World J Surg Oncol 2010; 8: 113.
- 37. Lin H, Li Z, Chen C, Luo X, Xiao J, Dong D, et al. Transcriptional and posttranscriptional mechanisms for oncogenic overexpression of ether à go-go K+ channel. PLoS ONE 2011; 6: e20362.